This drugmaker is developing breakthroughs like an ‘EpiPen for heart attacks.’ The market has yet to give it credit
RSS SUMMARY · AGGREGATED FROM CNBC
The key to its growth are a non-opioid pain reliever, a potential blockbuster lupus treatment and a drug that has been dubbed an "EpiPen for heart attacks."
The key to its growth are a non-opioid pain reliever, a potential blockbuster lupus treatment and a drug that has been dubbed an "EpiPen for heart attacks."
The key to its growth are a non-opioid pain reliever, a potential blockbuster lupus treatment and a drug that has been dubbed an "EpiPen for heart attacks."
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
Business
The May jobs report will be released Friday. Here’s what to expect
CNBC·1h ago·3 min read
US
Sen. Bill Cassidy signs onto brief calling ‘anti-weaponization’ fund a ‘dire threat’
CNBC·2h ago·3 min read
US
Quantinuum stock opens at $68 per share after IPO
CNBC·3h ago·3 min read
Business
Long-term unemployment is surging in the U.S. There are hidden costs for workers and the economy
CNBC·4h ago·3 min read
Related